New drug combo tried for tough blood cancers

NCT ID NCT03772925

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested two chemotherapy drugs, pevonedistat and belinostat, in 18 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to prior treatment. The main goal was to find the safest dose and understand side effects. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT MYELODYSPLASTIC SYNDROME REFRACTORY ACUTE MYELOID LEUKEMIA REFRACTORY MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States
Moffitt Cancer Center - McKinley Campus

Tampa, Florida, 33612, United States
Moffitt Cancer Center-International Plaza

Tampa, Florida, 33607, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390, United States
Virginia Commonwealth University/Massey Cancer Center

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.